Rapt therapeutics, inc. (RAPT)
Income statement / Yearly
Dec'19Dec'18
Operating expenses:
Research and development

34,910

31,767

General and administrative

8,719

5,180

Total operating expenses

43,629

36,947

Loss from operations

-43,629

-36,947

Other income
Other income, net

1,292

800

Net loss before taxes

-42,337

-36,147

Provision for income taxes

660

-

Net loss

-42,997

-36,147

Other comprehensive loss:
Foreign currency translation adjustment

24

-4

Total comprehensive loss

-42,973

-36,151

Net loss per share, basic and diluted

9.89

58.09

Weighted average number of shares used in computing net loss per share, basic and diluted

4,346

622